Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908347 | 0.89 | PDGFRB (0.75) | PDGFRBPDGFRAALOX15MAPK1EGFR | |
| SCHEMBL3910327 | 0.86 | PDGFRB (0.78) | PDGFRBPDGFRAMAPK1EGFRERBB2 | |
| SCHEMBL6381492 | 0.75 | EGFR (0.71) | EGFRERBB2 | |
| SCHEMBL3908370 | 0.75 | PDGFRB (1.00) | PDGFRBPDGFRAALOX15MAPK1EGFR | |
| SCHEMBL780389 | 0.73 | MAP4K4 (0.50) | PDGFRBPDGFRAMAPK1EGFRAPP | |
| SCHEMBL18171881 | 0.73 | PDGFRB (0.61) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL3911842 | 0.70 | PDGFRB (0.74) | PDGFRBPDGFRAEGFRKDM4EALDH1A1 | |
| SCHEMBL22792292 | 0.70 | ALOX15 (0.44) | PDGFRBPDGFRAALOX15MAPK1APP | |
| SCHEMBL782040 | 0.68 | HRH4 (0.46) | PDGFRBPDGFRA | |
| SCHEMBL3917671 | 0.68 | FBP1 (0.59) | PDGFRBPDGFRAMAPK1EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550597-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, ABL1 | PDGFRB 39/4885PDGFRA 45/4885ALOX15 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.